The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
August 18th 2025
FDA approves semaglutide for treating MASH, offering new hope for affected individuals.
Review of the 2022 ACCE Guidelines for Non-Alcoholic Fatty Liver Disease
November 10th 2022The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.
Read More
US Residents of Mexican Descent Show Higher Liver Cancer Risk in Successive Generations
September 20th 2022Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.
Read More